While the maximal IFN-γ release was cell-line dependent, the IFN-γ fold change at saturating concentrations across ovarian cancer cell lines treated with LYPD1-directed TCBs followed the same rank order as the FACS-binding EC50s. Here, IFNG is linked to ovarian cancer.